leisure time -WSS

leisure time

author：focus 2025-09-27 16:35:45 - browse：3474

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： As demand for Covid shots wanes, Moderna seeks its next success

hotspot

WSS

Microbiome research is starting to find links to chronic diseases

Senate HELP committee spars over health care workforce policies

How one medical school became remarkably diverse

Psychedelics group wrestles with new pharma identity

Bright Health sells Medicare Advantage business to Molina

Medicare proposal to cover medical devices draws a mixed reaction

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Apple is now the first public company to be valued at $3 trillion

The high cost of giving birth even with insurance

How one medical school became remarkably diverse

Medicare proposal to cover medical devices draws a mixed reaction

FDA approval of Sarepta Duchenne genetic therapy gives me hope

It's been 20 years since Dolly the sheep. Where's my clone?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why are Kaiser Permanente staff considering a strike?

New air purifier tech could be key to improving indoor air quality

Second xenotransplant done with gene

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Second xenotransplant done with gene

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CDC advisers recommend seasonal use of Pfizer RSV shot

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

As demand for Covid shots wanes, Moderna seeks its next success

hotspot

hotspot

hotspot

explore